Faculty Opinions recommendation of Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors.

Author(s):  
Jeffrey Evans
Sign in / Sign up

Export Citation Format

Share Document